Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of QLC5508 versus investigator's choice chemotherapy in previously treated advanced or metastatic esophageal squamous cell carcinoma
CTR20260811Phase 3Active
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of MHB088C in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Minghui Pharmaceutical, Inc.. Started Apr 2026; status: active.
02
Drugs
MHB088C
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20260811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260811.